-
Two Biocon Biologics Denosumab Biosimilars Approved by MHRA
07 Jul 2025 18:58 GMT
… The denosumab biosimilars mark Biocon’s third and fourth … adults with active psoriatic arthritis or moderately to … 5).
References
1. Biocon Biologics. Biocon Biologics Receives MHRA UK … 7, 2025.
5. Biocon Biologics. Biocon Biologics Receives MHRA Approval …
-
Biocon’s Ustekinumab Biosimilar Gets MHRA Approval
29 May 2025 17:12 GMT
… biosimilar acceptance in treating psoriasis, arthritis, and Crohn’s disease.
… reference biologic.
References
1. Biocon Biologics. Biocon Biologics Receives MHRA Approval … Feb. 18, 2025.
5. Biocon Biologics. Biocon Biologics Completes Acquisition of Viatris …
-
Biocon Biologics receives MHRA approval for YESINTEK
27 May 2025 16:03 GMT
… biosimilars company and subsidiary of Biocon, has announced that the Medicines … , and adults with active psoriatic arthritis or moderately to severely active …
-
Biocon Biologics receives UK MHRA marketing approval for Yesintek, biosimilar of ustekinumab
26 May 2025 09:45 GMT
… biosimilars company and subsidiary of Biocon received the approval from the … , and adults with active psoriatic arthritis or moderately to severely active …
-
Biocon Biologics psoriasis biosimilar receives UK regulator nod
26 May 2025 06:15 GMT
… , the biosimilars arm of Biocon has received marketing approval from … , and adults with active psoriatic arthritis or moderately to severely active …
-
Biocon Biologics receives UK MHRA approval for YESINTEK, Biosimilar Ustekinumab
25 May 2025 11:08 GMT
… BBL), a subsidiary of Biocon Ltd., has announced that … adults with active psoriatic arthritis and moderately to severely … United Kingdom. In parallel, Biocon Biologics also recently received … Economic Area (EEA).
Biocon Biologics continues its efforts …
-
Biocon Biologics debuts its psoriasis biosimilar in Japan
21 May 2025 17:16 GMT
… of psoriasis vulgaris and psoriatic arthritis (PsA) and will be commercialized … regulatory approval, the release stated.
Biocon Biologics has already launched Ustekinumab … control chronic inflammation.
As per Biocon, clinical studies showed that Yesintek …
-
Biocon Biologics and Yoshindo expand access to Ustekinumab Biosimilar in Japan
21 May 2025 11:03 GMT
… , developed and manufactured by Biocon Biologics, is commercialized and … of psoriasis vulgaris and psoriatic arthritis (PsA).
In April 2024, … .
Source : Equity Bulls
Keywords
Biocon
INE376G01013
Biotechnology
BioconBiologics
CommercialPartner
Yoshido …
-
Biocon Biologics launches Ustekinumab biosimilar in Japan after US, Europe rollout
21 May 2025 09:13 GMT
… Ustekinumab, developed and manufactured by Biocon Biologics, is being commercialised … vulgaris and psoriatic arthritis (PsA).
In April 2024, Biocon Biologics entered into … in Japan upon regulatory approval.
Biocon Biologics’ biosimilar Ustekinumab BS …
-
Biocon subsidiary and Yoshindo expand access to Ustekinumab Biosimilar in Japan
21 May 2025 06:06 GMT
… ustekinumab, developed and manufactured by Biocon Biologics, is being marketed and … psoriatic arthritis (PsA). The biosimilar was developed and manufactured by Biocon Biologics … in Japan after regulatory approval.
Biocon Biologics had earlier launched the …
About
© 1995-2025